• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics to Participate in Upcoming Investor Conferences

By: Autolus Therapeutics plc via GlobeNewswire
March 05, 2025 at 07:00 AM EST

LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences.

Jefferies Biotech on the Beach Summit
Management to host investor meetings
Date: March 11, 2025
Location: Miami, FL

Leerink Global Biopharma Conference
Fireside Chat Presentation
Date and time: March 12, 2025; 8:40am EDT / 12:40pm GMT
Location: Miami, FL
Presenter: Chief Executive Officer Dr. Christian Itin

A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.

Contact:

Amanda Cray
+1 617-967-0207
a.cray@autolus.com

Olivia Manser
+44 7780 471 568
o.manser@autolus.com


Primary Logo

More News

View More
Why Lyft’s Stock Volume Just Spiked—Is an EV Partnership Near?
Today 15:12 EDT
Via MarketBeat
Tickers LCID LYFT UBER
Global Value: 3 Stocks Under $10 Riding a Weak Dollar
Today 13:39 EDT
Via MarketBeat
Topics Economy Government
Tickers KMB MFG SUZ TSM
3 Great Growth Stocks to Buy-and-Hold for the Next 10 Years
Today 11:07 EDT
Via MarketBeat
Tickers CCJ FIX FTNT
NVIDIA: A Major Indicator Just Flashed Sell, But Should You?
Today 10:18 EDT
Via MarketBeat
Tickers NVDA
Why Coca-Cola Stock Is a Top Pick for Traders Today
Today 9:54 EDT
Via MarketBeat
Tickers KO
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap